We just received data on a new analyst forecast for $RNA. Barclays gave a rating of 'Overweight' for $RNA.
$RNA Analyst Ratings
Wall Street analysts have issued reports on $RNA in the last several months. We have seen 12 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 08/08/2025
- Goldman Sachs issued a "Buy" rating on 07/10/2025
- Cantor Fitzgerald issued a "Overweight" rating on 06/27/2025
- Wolfe Research issued a "Outperform" rating on 06/17/2025
- Raymond James issued a "Strong Buy" rating on 06/11/2025
- Citigroup issued a "Buy" rating on 06/10/2025
- B of A Securities issued a "Buy" rating on 06/09/2025
To track analyst ratings and price targets for $RNA, check out Quiver Quantitative's $RNA forecast page.
$RNA Price Targets
Multiple analysts have issued price targets for $RNA recently. We have seen 12 analysts offer price targets for $RNA in the last 6 months, with a median target of $66.5.
Here are some recent targets:
- Gena Wang from Barclays set a target price of $62.0 on 08/08/2025
- Keay Nakae from Chardan Capital set a target price of $75.0 on 08/08/2025
- Corinne Johnson from Goldman Sachs set a target price of $55.0 on 07/10/2025
- Eric Schmidt from Cantor Fitzgerald set a target price of $96.0 on 06/27/2025
- Andy Chen from Wolfe Research set a target price of $55.0 on 06/17/2025
- Michael Freeman from Raymond James set a target price of $65.0 on 06/11/2025
- Geoff Meacham from Citigroup set a target price of $75.0 on 06/10/2025
$RNA Insider Trading Activity
$RNA insiders have traded $RNA stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $RNA stock by insiders over the last 6 months:
- W. MICHAEL FLANAGAN (Chief Scientific Officer) has made 0 purchases and 3 sales selling 51,780 shares for an estimated $1,626,175.
- SARAH BOYCE (President and CEO) sold 31,540 shares for an estimated $979,563
- KATHLEEN P. GALLAGHER (Chief Program Officer) has made 0 purchases and 6 sales selling 24,411 shares for an estimated $744,998.
- STEVEN GEORGE HUGHES (Chief Medical Officer) sold 9,578 shares for an estimated $297,490
- MICHAEL F MACLEAN (Chief Financial Officer) sold 7,935 shares for an estimated $246,424
- TERESA MCCARTHY (Chief Human Resources Officer) sold 7,778 shares for an estimated $241,583
- JOHN B MORIARTY (Chief Legal Officer) sold 2,245 shares for an estimated $81,291
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RNA Hedge Fund Activity
We have seen 112 institutional investors add shares of $RNA stock to their portfolio, and 120 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 4,373,686 shares (+62.0%) to their portfolio in Q1 2025, for an estimated $129,111,210
- WELLINGTON MANAGEMENT GROUP LLP added 1,578,459 shares (+19.5%) to their portfolio in Q1 2025, for an estimated $46,596,109
- BANK OF AMERICA CORP /DE/ added 1,395,900 shares (+781.6%) to their portfolio in Q1 2025, for an estimated $41,206,968
- FMR LLC removed 894,542 shares (-5.4%) from their portfolio in Q1 2025, for an estimated $26,406,879
- BOXER CAPITAL MANAGEMENT, LLC removed 862,388 shares (-49.9%) from their portfolio in Q1 2025, for an estimated $25,457,693
- RTW INVESTMENTS, LP added 814,056 shares (+10.3%) to their portfolio in Q1 2025, for an estimated $24,030,933
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 771,158 shares (+inf%) to their portfolio in Q1 2025, for an estimated $22,764,584
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
